New drug combo aims to shrink rectal tumors before surgery

NCT ID NCT04503694

Ongoing Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining two drugs (nivolumab and regorafenib) with short-course radiation can shrink tumors in people with stage II or III rectal cancer. About 72 participants will receive the drugs before and after radiation, followed by surgery or a watch-and-wait approach if the tumor disappears. The goal is to see how many patients have no cancer cells left after treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER STAGE II are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER (STAGE III) RECTAL CANCER STAGE II

Contacts and locations

Show contact details

Locations

AZ Groeninge

Kortrijk, 8500, Belgium
CHR Namur

Namur, 5000, Belgium
CHU Ambroise Paré

Mons, 7000, Belgium
Chirec Delta

Brussels, 1160, Belgium
Cliniques Universitaires Saint-Luc

Brussels, 1200, Belgium
Grand Hopital de Charleroi

Gilly, 6060, Belgium
Institut Jules Bordet

Anderlecht, 1070, Belgium
UZ Gent

Ghent, 9000, Belgium
UZAntwerpen

Edegem, 2650, Belgium